Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
36
BNTX Quote, Financials, Valuation and Earnings
Last price:
$113.18
Seasonality move
:
15.33%
Day range:
$109.80 - $115.34
52-week range:
$76.53 - $131.49
Dividend yield:
0%
P/E ratio:
184.86x
P/S ratio:
8.26x
P/B ratio:
1.27x
Volume:
924.8K
Avg. volume:
1M
1-year change:
10%
Market cap:
$27.1B
Revenue:
$4.1B
EPS (TTM):
-$2.11
Analysts' Opinion
-
Consensus RatingBioNTech SE has received a consensus rating of Buy. The company's average rating is a Buy based on 11 Buy ratings, 5 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $137.54, BioNTech SE has an estimated upside of 21.63% from its current price of $113.08.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $120.95 representing -6.96% downside risk from its current price of $113.08.
Fair Value
-
According to the consensus of 16 analysts, BioNTech SE has 21.63% upside to fair value with a price target of $137.54 per share.
BNTX vs. S&P 500
-
Over the past 5 trading days, BioNTech SE has underperformed the S&P 500 by -4.16% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
BioNTech SE does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
BioNTech SE has grown year-over-year revenues for 1 quarter straight. In the most recent quarter BioNTech SE reported revenues of $1.4B.
Earnings Growth
-
BioNTech SE has grown year-over-year earnings for 1 quarter straight. In the most recent quarter BioNTech SE reported earnings per share of $0.89.
Enterprise value:
8.7B
EV / Invested capital:
0.40x
Price / LTM sales:
8.26x
EV / EBIT:
--
EV / Revenue:
2.64x
PEG ratio (5yr expected):
--
EV / Free cash flow:
8.46x
Price / Operating cash flow:
26.48x
Enterprise value / EBITDA:
72.89x
Gross Profit (TTM):
$2.8B
Return On Assets:
-2.06%
Net Income Margin (TTM):
-15.17%
Return On Equity:
-2.35%
Return On Invested Capital:
-2.32%
Operating Margin:
0.84%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $20.4B | $6.9B | $3.3B | $974.8M | $1.4B | |
| Gross Profit | $16.7B | $6.3B | $2.8B | $798.6M | $1.2B | |
| Operating Income | $14.9B | $3.7B | -$782.8M | $79.6M | $11.5M | |
| EBITDA | $15.5B | $3.3B | -$396.9M | $294.7M | $232.2M | |
| Diluted EPS | $43.80 | $11.53 | -$2.11 | $0.72 | $0.89 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.3B | $15.7B | $20.9B | $19.8B | $20.6B | |
| Total Assets | $1.7B | $16.5B | $22.3B | $23.5B | $25B | |
| Current Liabilities | $315.2M | $5.7B | $3.9B | $1.9B | $2.8B | |
| Total Liabilities | $612.3M | $6.4B | $4.2B | $2.5B | $3.7B | |
| Total Equity | $1.1B | $10.1B | $18.1B | $21B | $21.3B | |
| Total Debt | $206.2M | $332.5M | $269.3M | $213.7M | $272.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $12.6B | $6.4B | $1.6B | $877.1M | -$672.5M | |
| Cash From Investing | $6.5M | -$4.8B | -$5.8B | -$1.3B | -$215M | |
| Cash From Financing | -$1.4B | -$965.9M | -$51.7M | -$337.9M | -$9.4M | |
| Free Cash Flow | $12.3B | $5.7B | $1B | $713.1M | -$770.2M | |
BNTX
Sector
Market Cap
$27.1B
$44.6M
Price % of 52-Week High
86%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.68%
1-Year Price Total Return
10%
-29.09%
Beta (5-Year)
0.217
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$116.01
200-day SMA
Buy
Level
$98.17
Bollinger Bands (100)
Buy
Level
92.41 - 120.25
Chaikin Money Flow
Buy
Level
121M
20-day SMA
Sell
Level
$117.27
Relative Strength Index (RSI14)
Sell
Level
47.60
ADX Line
Buy
Level
11.87
Williams %R
Neutral
Level
-77.5819
50-day SMA
Sell
Level
$113.33
MACD (12, 26)
Buy
Level
0.49
25-day Aroon Oscillator
Buy
Level
56
On Balance Volume
Neutral
Level
106.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (7.3363)
Buy
CA Score
(Annual)
Level (1.4765)
Buy
Beneish M-Score
(Annual)
Level (-3.4953)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (-0.3705)
Buy
Piotroski F Score
(Annual)
Level (7)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
Stock Forecast FAQ
In the current month, BNTX has received 11 Buy ratings 5 Hold ratings, and 0 Sell ratings. The BNTX average analyst price target in the past 3 months is $137.54.
-
Where Will BioNTech SE Stock Be In 1 Year?
According to analysts, the consensus estimate is that BioNTech SE share price will rise to $137.54 per share over the next 12 months.
-
What Do Analysts Say About BioNTech SE?
Analysts are divided on their view about BioNTech SE share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that BioNTech SE is a Sell and believe this share price will drop from its current level to $120.95.
-
What Is BioNTech SE's Price Target?
The price target for BioNTech SE over the next 1-year time period is forecast to be $137.54 according to 16 Wall Street analysts, 11 of them rate the stock a Buy, 0 rate the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is BNTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for BioNTech SE is a Buy. 11 of 16 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BNTX?
You can purchase shares of BioNTech SE via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase BioNTech SE shares.
-
What Is The BioNTech SE Share Price Today?
BioNTech SE was last trading at $113.18 per share. This represents the most recent stock quote for BioNTech SE. Yesterday, BioNTech SE closed at $113.08 per share.
-
How To Buy BioNTech SE Stock Online?
In order to purchase BioNTech SE stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
